EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD

Samy Suissa, Sophie Dell'Aniello, Pierre Ernst

CHEST · 2025

DOI: 10.1016/j.chest.2024.10.025 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CHEST, 2025. Verfasst von Samy Suissa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Montreal, QC; Department of Epidemiology, Biostatistics and Occupatio…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Adrenergic beta-2 Receptor Agonists, Adrenal Cortex Hormones, Muscarinic Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Canada Foundation for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recent treatment guidelines for COPD have replaced the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA). However, the corresponding trials reported numerically higher incidences of cardiovascular adverse events with triple therapy compared with LABA-ICS. RESEARCH QUESTION: Does single-inhaler triple therapy increase the incidence of major adverse cardiovascular events, compared with LABA-ICS, in a real-world clinical practice setting? STUDY DESIGN AND METHODS: We identified a cohort of patients with COPD aged ≥ 40 years treated during 2017-2021 from the UK's Clinical Practice Research Datalink. Among LAMA-naive patients, initiators of single-inhaler triple therapy were matched 1:1 to LABA-ICS users on time-conditional propensity scores. They were compared on the incidence of major adverse cardiovascular events (MACEs), defined as hospitalization for myocardial infarction or stroke, or all-cause-mortality, over 1 year. RESULTS: The cohort included 10,255 initiators of triple therapy and 10,255 matched users of LABA-ICS. The incidence rate of MACEs was 11.3 per 100 per year with triple therapy compared with 8.8 per 100 per year for LABA-ICS. The corresponding adjusted hazard ratio (HR) of MACEs with triple therapy was 1.28 (95% CI, 1.05-1.55), relative to LABA-ICS; however, the increase was mainly in the first 4 months (HR, 1.41; 95% CI, 1.14-1.74). The HR of all-cause death was 1.31 (95% CI, 1.06-1.62), whereas for acute myocardial infarction and stroke hospitalization it was 1.00 (95% CI, 0.56-1.79) and 1.06 (95% CI, 0.48-2.36), respectively, with triple therapy, relative to LABA-ICS. INTERPRETATION: In a real-world setting of COPD treatment, patients who initiated single-inhaler triple therapy had an increased incidence of MACEs compared with similar patients treated with an LABA-ICS inhaler. This small increase was due to the all-cause mortality component, occurring mainly in the first 4 months after treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAdrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesMuscarinic AntagonistsHumansAdministration, InhalationMaleFemaleAgedMiddle AgedUnited KingdomDrug Therapy, CombinationIncidenceNebulizers and VaporizersCardiovascular Diseases

Stichwörter der Autor:innen

cohort studiesmajor adverse cardiovascular events (MACE)mortalitynew-user designreal-world evidence

Substanzen

Adrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesMuscarinic Antagonists

Autor:innen und Institutionen

  • Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Montreal, QC; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; Department of Med…
  • Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Montreal, QC.
  • Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Montreal, QC; Department of Medicine, McGill University, Montreal, QC, Canada.

Förderung

  • Canadian Institutes of Health Research
  • Canada Foundation for Innovation

Zitieren

APA

Suissa, S., Dell'Aniello, S., & Ernst, P. (2025). Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD. CHEST. https://doi.org/10.1016/j.chest.2024.10.025

Vancouver

Suissa S, Dell'Aniello S, Ernst P. Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD. CHEST. 2025. doi:10.1016/j.chest.2024.10.025

BibTeX
@article{Suissa2025,
  author = {Suissa, Samy and Dell'Aniello, Sophie and Ernst, Pierre},
  title = {Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2024.10.025}
}
Kostenlos starten →